FOLD תחזית צמיחת רווחים לשנה הבאה amicusrx.com

Amicus Therapeutics (FOLD) is developing a portfolio of drugs for rare genetic pathologies in Europe and the US. Revenues are based on the supply of high-cost enzymes for the treatment of Pompe and Fabry diseases. The history of forward earnings per share estimates demonstrates a stabilization of market expectations, where the metric value stands at 82.40. Effective collaboration with contract manufacturers ensures flexible inventory management and the scaling of drug production.

This indicator synthesizes analyst consensus forecasts and financial statements, measuring expected earnings per share (EPS) dynamics to assess the future value of the business. By analyzing the forward EPS forecast for the coming year, an investor determines whether the asset's current price is justified, which is critical for Amicus Therapeutics (FOLD) during its expansion of monopoly therapies for Pompe disease and its capture of the rare disease niche.